BIOM starts Phase II prostate cancer trial

Biomira (BIOM; TSE:BRA) began a Phase II trial of its BLP25 vaccine to treat recurrent prostate cancer in 20 patients who have had a radical prostatectomy at least 6 months prior to entry. The primary...